LabConnect and OmniScience Partner to Launch First AI Solution for Real-Time Clinical Lab Data Analysis
LabConnect and OmniScience have partnered to create the first AI-driven platform that provides real-time insights from clinical trial lab data, potentially accelerating drug development timelines and improving trial outcomes.
LabConnect, a global provider of central laboratory services, has announced a strategic collaboration with artificial intelligence company OmniScience to develop the industry's first agentic AI solution for live clinical laboratory data. The partnership aims to address longstanding challenges in clinical trial data management by providing sponsors with intelligent, real-time insights from complex lab datasets.
Clinical trial lab data has traditionally been siloed, complex, and subject to processing delays, which often results in slow decision-making and increased operational risks. The new solution combines LabConnect's expertise in central lab testing and data management with OmniScience's Vivo platform, an AI-native clinical trial intelligence platform designed to unify disparate data sources. This integration enables trial sponsors to automate oversight processes and identify risk signals more efficiently, potentially accelerating trial timelines and improving overall outcomes.
The specialized implementation, known as Vivo-Lab, streamlines laboratory workflows by detecting critical trends, anomalies, and site-level discrepancies as they occur. This capability allows clinical, operational, safety, and data science teams to transition from reactive to proactive oversight in one of clinical research's most complex data streams. According to Angela Holmes, CEO and Co-Founder of OmniScience, the partnership extends their mission to help trial teams see and act faster by transforming lab data into actionable intelligence that sponsors can trust.
Wes Wheeler, CEO of LabConnect, emphasized that the collaboration represents a shift from static lab reports to dynamic, actionable intelligence. The integration provides clinical operations teams with the speed, agility, and precision needed to make smarter decisions, improve trial efficiency, and potentially bring therapies to patients more quickly. Both organizations have committed to innovation in clinical development, combining LabConnect's technology-driven laboratory operations with OmniScience's AI-native approach to trial intelligence. More information about LabConnect's services can be found at https://www.labconnect.com.
The partnership underscores the growing importance of artificial intelligence in transforming clinical research methodologies. By addressing data fragmentation and delay issues that have long plagued clinical trials, this collaboration could set a new standard for how pharmaceutical companies and research organizations manage and utilize laboratory data throughout the drug development lifecycle.